SCHEMBL21085149

SCHEMBL21085149

O=C(O)CC1C[CH]CCC1C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A12 P48065 4/20 0.39
SLC6A11 P48066 4/20 0.39
SLC6A13 Q9NSD5 4/20 0.39
GABRR1 P24046 4/20 0.33
GABRR2 P28476 1/20 0.33
HSD11B1 P28845 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
SLC1A2 P43004 2/20 0.31
MAPK1 P28482 1/20 0.31
TSHR P16473 1/20 0.31
THPO P40225 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
GRIK1 P39086 1/20 0.31
GRM5 P41594 1/20 0.31
GRIA1 P42261 1/20 0.31
GRIA2 P42262 1/20 0.31
GRIA3 P42263 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21085021 0.84 SLC6A12 (0.39) SLC6A12SLC6A11SLC6A13GABRR1GABRR2
SCHEMBL21085088 0.82 GABRR1 (0.34) GABRR1GABRR2ALDH1A1
SCHEMBL21085031 0.81 SLC6A12 (0.43) SLC6A12SLC6A11SLC6A13GABRR1HSD11B1
SCHEMBL21085012 0.81 HSD17B10 (0.35) GABRR1GABRR2MEN1KMT2ATSHR
SCHEMBL21085017 0.78 GABRR1 (0.32) GABRR1GABRR2
SCHEMBL21085145 0.76 SLC6A12 (0.39) SLC6A12SLC6A11SLC6A13GABRR1SLC6A1
SCHEMBL21085029 0.76 POLB (0.31) GABRR1GABRR2
SCHEMBL21085075 0.73 SLC6A12 (0.40) SLC6A12SLC6A11SLC6A13GABRR1SLC6A1
SCHEMBL9800052 0.73 KDM4E (0.38) GABRR1SLC1A2ALDH1A1
SCHEMBL22902378 0.72 SLC6A12 (0.43) SLC6A12SLC6A11SLC6A13GABRR1GABRR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10759749-B2 Therapeutic agent for diabetes JCR PHARMACEUTICALS CO., LTD. (JP) 2020-09-01 US disclosed
EP-3508474-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR Pharmaceuticals Co., Ltd. (JP) 2019-07-10 EP disclosed
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES JCR PHARMACEUTICALS CO., LTD. (JP) 2019-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190202781-A1 NOVEL THERAPEUTIC AGENT FOR DIABETES GPR119, IAPP, DPP4 SLC6A12 1837/4885SLC6A11 1410/4885SLC6A13 2070/4885
US-10759749-B2 Therapeutic agent for diabetes GPR119, IAPP, DPP4 SLC6A12 925/4885SLC6A11 1206/4885SLC6A13 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.